REGN Stock AnalysisRegeneron Pharmaceuticals, Inc. · current price $793.96 (-1.70% today)
Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.
Reading REGN’s price and volume history…
Checking the areas that decide this thesis…
AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.
Reading REGN’s filings…
| Quarter | EPS | Est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-30 | $11.83 | $9.64 | +22.7% | Beat |
| 2025-12-31 | $11.44 | $10.75 | +6.4% | Beat |
| 2026-03-31 | $9.47 | $8.90 | +6.4% | Beat |
| 2026-06-30 | $14.29 | $10.21 | +40.0% | Beat |
Regeneron Pharmaceuticals, Inc. (REGN) currently has a TickerMover Quant Score of 71/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.
TickerMover does not give buy or sell recommendations. REGN scores 71/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.
REGN's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.
Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.
Open the dashboard for REGN →
